Abbott posted strong organic growth of 11% in Q4 when excluding Covid testing sales. This year the stock will hit a milestone: 400 consecutive quarterly dividend payments. But consistency doesn't come ...

A new automation system from Abbott, designed to improve workflows in clinical lab settings, has been granted FDA approval. The system, GLP systems Track, uses a self-propelled carrier system that ...

ABT, is repositioning its business after ongoing challenges in its Nutrition segment. The company is advancing a major acquisition of Exact Sciences to expand into oncology diagnostics. Management is ...

Abbott Laboratories reported strong Q4 2023 earnings, with year-over-year growth in EPS and revenue. The company's 2024 guidance projects further growth and improved ...

In 2023, AI and the Magnificent 7 took the lead, leaving non-tech blue chip companies trailing behind in the rearview mirror. Abbott Laboratories had a difficult last three years, with its stock price ...

On Wednesday, Abbott Laboratories (NYSE:ABT) reported fourth-quarter sales of $10.97 billion, up 7.2% year over year, missing the consensus of $11.01 billion. Organic sales growth for the underlying ...

Abbott Laboratories (NYSE:ABT) received an FDA warning letter focused on the accuracy and testing of its FreeStyle Libre ...